BridgeBio Pharma (BBIO) wins FDA nod Attruby for rare heart disorder, ATTR-CM challenging Pfizer's (PFE) Vyndaqel. Read more ...

The U.S. Food and Drug Administration has approved BridgeBio's drug for a rare and deadly heart condition, the company said ...

The Food and Drug Administration approved on Friday a new medicine from BridgeBio for patients with a progressive heart ...

The approval of Attruby for transthyretin amyloidosis with cardiomyopathy begins a battle for control of a lucrative market ...

In this retrospective cohort study, decline in kidney function was frequent in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and was consistently associated with an increased risk of ...

Come join Medscape Education at the American Heart Association (AHA) 2024 Scientific Sessions in Chicago, IL, from November ...

HCM is a relatively common genetic cardiomyopathy that can be a challenge to diagnose, with about one in three patients misdiagnosed as having another cardiomyopathy. Genetic testing identifies a ...

In transthyretin amyloid cardiomyopathy (ATTR-CM), the assessment of functional capacity is of great importance. A distance < 300m covered in the 6-minute walk test (6MWT) is linked to a poorer ...

Switching to NEX-Z, also known as 2001, in development for the treatment of ATTR Amyloidosis. This multi-system disease primarily manifests as either cardiomyopathy due to amyloid deposits in the ...

Dilated cardiomyopathy is the most frequent cause ... Transthyretin-related cardiac amyloidosis is a progressive disease characterized by the deposition of amyloid protein fibrils in the heart.